文章基本信息

标题：LIGHTHOUSE illuminates therapeutics for a variety of diseases including COVID-19
本地全文：下载
作者：Hideyuki Shimizu ; Manabu Kodama ; Masaki Matsumoto 等
期刊名称：iScience
印刷版ISSN：2589-0042
出版年度：2022
卷号：25
期号：11
页码：1-24
DOI：10.1016/j.isci.2022.105314
语种：English
出版社：Elsevier
摘要：SummaryOne of the bottlenecks in the application of basic research findings to patients is the enormous cost, time, and effort required for high-throughput screening of potential drugs for given therapeutic targets. Here we have developed LIGHTHOUSE, a graph-based deep learning approach for discovery of the hidden principles underlying the association of small-molecule compounds with target proteins. Without any 3D structural information for proteins or chemicals, LIGHTHOUSE estimates protein-compound scores that incorporate known evolutionary relations and available experimental data. It identified therapeutics for cancer, lifestyle related disease, and bacterial infection. Moreover, LIGHTHOUSE predicted ethoxzolamide as a therapeutic for coronavirus disease 2019 (COVID-19), and this agent was indeed effective against alpha, beta, gamma, and delta variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are rampant worldwide. We envision that LIGHTHOUSE will help accelerate drug discovery and fill the gap between bench side and bedside.Graphical abstractDisplay OmittedHighlights•LIGHTHOUSE discovers therapeutics solely on the basis of the primary sequence•The predictions of LIGHTHOUSE against multiple diseases were experimentally correct•LIGHTHOUSE facilitates optimization of lead compounds as wellDrugs; Systems biology